Atria Investments Inc Grows Stake in CalciMedica, Inc. (NASDAQ:CALC)

Atria Investments Inc increased its position in CalciMedica, Inc. (NASDAQ:CALC) by 136.5% in the third quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm owned 26,503 shares of the company’s stock after purchasing an additional 15,296 shares during the quarter. Atria Investments Inc’s holdings in CalciMedica were worth $117,000 as of its most recent filing with the Securities & Exchange Commission.

Insiders Place Their Bets

In related news, major shareholder Sanderling Venture Partners Vi bought 86,867 shares of the stock in a transaction that occurred on Friday, November 1st. The shares were bought at an average cost of $3.75 per share, for a total transaction of $325,751.25. Following the completion of the transaction, the insider now owns 814,300 shares of the company’s stock, valued at approximately $3,053,625. This trade represents a 11.94 % increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director Fred A. Middleton bought 87,744 shares of the stock in a transaction that occurred on Friday, November 1st. The shares were bought at an average price of $3.75 per share, for a total transaction of $329,040.00. Following the completion of the transaction, the director now directly owns 814,300 shares of the company’s stock, valued at $3,053,625. This represents a 12.08 % increase in their position. The disclosure for this purchase can be found here. In the last quarter, insiders acquired 248,944 shares of company stock valued at $933,980. Corporate insiders own 41.55% of the company’s stock.

Analysts Set New Price Targets

Separately, HC Wainwright restated a “buy” rating and issued a $16.00 target price on shares of CalciMedica in a research note on Thursday, November 14th.

CalciMedica Price Performance

CALC stock opened at $3.45 on Monday. The firm has a market cap of $46.51 million, a PE ratio of -3.19 and a beta of 1.30. The business has a 50 day moving average of $3.94 and a 200 day moving average of $4.44. CalciMedica, Inc. has a twelve month low of $2.68 and a twelve month high of $8.38.

About CalciMedica

CalciMedica, Inc, a clinical-stage biopharmaceutical company, focuses on developing therapeutics for illnesses caused by inflammatory and immunologic processes and direct cellular damage. The company's lead product candidate comprises Auxora, an intravenous formulated small molecule calcium release-activated (CRAC) channel inhibitors, which is in phase 2 clinical trials for the treatment of acute pancreatitis, asparaginase induced pancreatic toxicity, and acute kidney injury, as well as severe COVID-19 pneumonia.